Navigation Links
PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
Date:3/17/2009

pharmanet.com/" target="_new">www.pharmanet.com.

Advisors

Skadden, Arps, Slate, Meagher & Flom, LLP acted as legal counsel and Jefferies & Company, Inc. acted as financial advisor to JLL for this transaction. Morgan, Lewis & Bockius LLP acted as legal counsel and UBS Investment Bank acted as financial advisor to PharmaNet. Latham & Watkins acted as legal counsel to PharmaNet's Board of Directors.

Important Information about the Tender Offer

This press release is neither an offer to purchase nor a solicitation of an offer to sell securities. The tender offer is being made pursuant to a Tender Offer Statement on Schedule TO (including the Offer to Purchase, the related Letter of Transmittal and other tender offer materials) filed by Parent, Purchaser and the Sponsors with the SEC on February 12, 2009. In addition, on February 12, 2009, PharmaNet filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC related to the tender offer. The Tender Offer Statement (and related materials) and the Solicitation/Recommendation Statement contain important information that should be read carefully before any decision is made with respect to the tender offer. Those materials may be obtained at no charge upon request to either Innisfree M&A Incorporated., the information agent for the tender offer at (888) 750-5834 (toll free) or to Jefferies & Company, Inc., the Dealer Manager for the tender offer at (888) 323-3302 (toll free). In addition, all of those materials (and all other offer documents filed with the SEC) are available at no charge on the SEC's website at www.sec.gov.

Forward-Looking Statements

Certain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation R
'/>"/>

SOURCE PharmaNet Development Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. PharmaNet Development Group Agrees to be Acquired by JLL Partners
4. PAREXEL Experts to Address Benefits of Rigorous Early Phase Development at Annual ASCPT Meeting
5. Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio
6. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
7. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
8. PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009
9. AMDL, Inc. Enters Into Collaboration Agreement to Advance Development of Its AMDL DR-70 (FDP) Cancer Test
10. Dr. James Cai Joins aTyr Pharma to Drive Clinical Development in Asia
11. AMPAC Fine Chemicals Announces the Inauguration of the New cGMP Continuous Processing Development Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 Glenn Keet, CEO ... Changing Landscape of EMR/EHR Clinical Data Integration with EDC ... place in Washington, DC on June 14th-18th. , During ... integrating EMR/EHR systems with EDC, and will examine the ... by eSource and electronic health records/electronic medical records integration. ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/27/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... a public offering of shares of its common ... stock and overallotment purchase rights to purchase shares ... stock, warrants and overallotment purchase rights are immediately ...
(Date:5/27/2015)... May 27, 2015 Expanding in a ... manufacturer Avalon Biomed Inc. recently inked a ... Mokuda Dental Co. Ltd. , the largest endodontic distributor ... the international market for Avalon Biomed, which manufactures Grey ... tricalcium silicate-based dental cements that have won renown from ...
Breaking Biology Technology:Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3
... Sept. 7 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced that it will ... data for,two of its anti-cancer antibody drug candidates. ... San Francisco on September 7-8,Arius will report recent ...
... Belgium and LUND, Sweden, September 7 ... Into Phase,II Clinical Development ThromboGenics NV (Euronext ... and co-development partner, BioInvent,International (Nordic Exchange: BINV), announce ... follow-up of all volunteers,in the first Phase I ...
... and James Weaver as Chairman, WALTHAM, Mass., Sept. ... today that Thomas Gerson has been named Chief,Financial Officer. ... the Board of Directors. In addition, Nazneen Aziz has ... "We are pleased to welcome Tom to Interleukin," said ...
Cached Biology Technology:Arius Features Preclinical Data on Antibody Candidates at Two Conferences 2Arius Features Preclinical Data on Antibody Candidates at Two Conferences 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 2ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 3ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 4ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 5Interleukin Genetics Announces Management and Board Appointments 2Interleukin Genetics Announces Management and Board Appointments 3Interleukin Genetics Announces Management and Board Appointments 4
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... and chemically modified graphene sheets in a wide variety ... of Texas at Austin engineering team led by Professor ... a host of important materials and applications such as ... plastic electronics. Graphene is a unique atom-thick, carbon-based ...
... help people who are not responding to Anti-Retroviral Therapy, ... of Immunology . Scientists looking at monkeys with the ... virus levels in the blood to undetectable levels, by ... Anti-Retroviral Therapy (ART). Simian Immunodeficiency Virus (SIV) is ...
... a common cause of back pain has picked up one ... research paper produced by the team of surgeons, engineers and ... of three categories of the annual ISSLS Prize for Lumbar ... Study of the Lumbar Spine (ISSLS), the accolade is designed ...
Cached Biology News:Engineers develop method to disperse chemically modified graphene in organic solvents 2Potential new HIV drug may help patients not responding to treatment 2Potential new HIV drug may help patients not responding to treatment 3International prize for Nottingham spine research 2
... (MSTA) slides were designed to study protein expression ... species. Tissue slices from three different species ... then be treated as a single histological slide ... hybridization. This format allows a rapid ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~5 kDa thymosin beta4 protein....
Biology Products: